About: ISG15 and immune diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ISG15 and immune diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ISG15 and immune diseases
Creator	Chung, Chin Jeon, Young Yoo, Hee
topic	covid:fc8ccab719f88424dc903e536ae75dbf936ce026#this
Source	Elsevier; Medline; PMC
abstract	Abstract ISG15, the product of interferon (IFN)-stimulated gene 15, is the first identified ubiquitin-like protein, consisting of two ubiquitin-like domains. ISG15 is synthesized as a precursor in certain mammals and, therefore, needs to be processed to expose the C-terminal glycine residue before conjugation to target proteins. A set of three-step cascade enzymes, an E1 enzyme (UBE1L), an E2 enzyme (UbcH8), and one of several E3 ligases (e.g., EFP and HERC5), catalyzes ISG15 conjugation (ISGylation) of a specific protein. These enzymes are unique among the cascade enzymes for ubiquitin and other ubiquitin-like proteins in that all of them are induced by type I IFNs or other stimuli, such as exposure to viruses and lipopolysaccharide. Mass spectrometric analysis has led to the identification of several hundreds of candidate proteins that can be conjugated by ISG15. Some of them are type I IFN-induced proteins, such as PKR and RIG-I, and some are the key regulators that are involved in IFN signaling, such as JAK1 and STAT1, implicating the role of ISG15 and its conjugates in type I IFN-mediated innate immune responses. However, relatively little is known about the functional significance of ISG15 induction due to the lack of information on the consequences of its conjugation to target proteins. Here, we describe the recent progress made in exploring the biological function of ISG15 and its reversible modification of target proteins and thus in their implication in immune diseases.
has issue date	2010-05-31(xsd:dateTime)
bibo:doi	10.1016/j.bbadis.2010.02.006
bibo:pmid	20153823
has license	els-covid
sha1sum (hex)	fc8ccab719f88424dc903e536ae75dbf936ce026
schema:url	https://doi.org/10.1016/j.bbadis.2010.02.006
resource representing a document's title	ISG15 and immune diseases
has PubMed Central identifier	PMC7127291
has PubMed identifier	20153823
schema:publication	Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
resource representing a document's body	covid:fc8ccab719f88424dc903e536ae75dbf936ce026#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/fc8ccab719f88424dc903e536ae75dbf936ce026
is schema:about of	named entity 'C-terminal' named entity 'mammals' named entity 'consequences' named entity 'IFN' named entity 'FUNCTIONAL' named entity 'EFP' named entity 'SYNTHESIZED' named entity 'LACK' named entity 'ENZYMES' named entity 'PROTEINS' named entity 'TYPE I INTERFERONS' named entity 'NEEDS' named entity 'JAK1' named entity 'THESE' named entity 'KEYWORDS' named entity 'UBCH8' named entity 'SPECIFIC PROTEIN' named entity 'ITS' named entity 'TARGET' named entity 'CERTAIN' named entity 'INVOLVED' named entity 'UBIQUITIN-LIKE PROTEIN' named entity 'DESCRIBE' named entity 'MASS' named entity 'TYPE I' named entity 'LIPOPOLYSACCHARIDE' named entity 'IFN' named entity 'EXPOSE' named entity 'PROGRESS' named entity 'RIG-I' named entity 'UBE1L' named entity 'REVERSIBLE' named entity 'CONJUGATION' named entity 'IDENTIFIED' named entity 'INDUCTION' named entity 'PKR' named entity 'PRECURSOR' named entity 'UBIQUITIN' named entity 'SIGNIFICANCE' named entity 'INDUCED' named entity 'ONE OF' named entity 'LIKE' named entity 'LIGASES' named entity 'MODIFICATION' named entity 'MAMMALS' named entity 'RECENT' named entity 'CASCADE' named entity 'ABOUT' named entity 'UNIQUE' named entity 'REGULATORS' named entity 'PRODUCT' named entity 'SIGNALING' named entity 'HERC5' named entity 'ROLE' named entity 'IMMUNE' named entity 'CANDIDATE' named entity 'EXPLORING' named entity 'KNOWN' named entity 'STIMULATED' named entity 'BIOLOGICAL FUNCTION' named entity 'CONSEQUENCES' named entity 'ISG15' named entity 'ISG15' named entity 'IMMUNE' named entity 'IDENTIFICATION' named entity 'E2 ENZYME' named entity 'HERE' named entity 'THEIR' named entity 'DUE TO' named entity 'INTERFERON ' named entity 'ANALYSIS' named entity 'IMMUNE RESPONSES' named entity 'INFORMATION' named entity 'VIRAL INFECTION' named entity 'UBP43' named entity 'C-TERMINAL GLYCINE RESIDUE' named entity 'STIMULI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software